A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E Given as Monotherapy Followed By Expansion Cohorts in Subjects with Malignant Solid Tumors that Express Nectin-4
Description: 

This is an open-label, multi-center, study examining the safety and pharmacokinetics (PK) of AGS-22M6E administered as monotherapy in subjects with malignant solid tumors that express Nectin-4.

Study Number: 

PH 215412

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01409135

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.